Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study

BACKGROUND: A programmed cell death protein-1 (PD-1) inhibitor combined with lenvatinib and Gemox chemotherapy as first-line therapy demonstrated high anti-tumor activity against biliary tract cancer in phase II clinical trials. Herein, we aimed to investigate the efficacy and safety for advanced in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chengpei, Li, Hu, Yang, Xiaobo, Wang, Shanshan, Wang, Yunchao, Zhang, Nan, Wang, Yanyu, Xue, Jingnan, Zhang, Longhao, Ning, Cong, Yang, Xu, Xun, Ziyu, Chao, Jiashuo, Long, Junyu, Sang, Xinting, Zhu, Zhenyu, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412480/
https://www.ncbi.nlm.nih.gov/pubmed/37247023
http://dx.doi.org/10.1007/s00262-023-03466-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412480/
https://www.ncbi.nlm.nih.gov/pubmed/37247023
http://dx.doi.org/10.1007/s00262-023-03466-8

Ejemplares similares